Biodesix (NASDAQ:BDSX) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Biodesix (NASDAQ:BDSX) announced its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01, Zacks reports. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The firm had revenue of $20.43 million for the quarter, compared to the consensus estimate of $19.92 million. Biodesix updated its FY 2025 guidance to EPS.

Biodesix Stock Up 1.0 %

Biodesix stock opened at $0.72 on Wednesday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The business’s 50-day simple moving average is $1.11 and its two-hundred day simple moving average is $1.41. The company has a market cap of $104.74 million, a PE ratio of -1.85 and a beta of 1.06. Biodesix has a fifty-two week low of $0.64 and a fifty-two week high of $2.04.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Biodesix in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $2.95.

Insider Buying and Selling at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the sale, the chief executive officer now owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 128,702 shares of company stock worth $118,406. 69.20% of the stock is currently owned by insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.